2,716 Shares in Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) Acquired by XML Financial LLC

XML Financial LLC purchased a new position in Jazz Pharmaceuticals PLC (NASDAQ:JAZZ - Free Report) during the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor purchased 2,716 shares of the specialty pharmaceutical company's stock, valued at approximately $337,000.

Several other institutional investors also recently bought and sold shares of JAZZ. Versant Capital Management Inc boosted its holdings in Jazz Pharmaceuticals by 9.4% in the first quarter. Versant Capital Management Inc now owns 1,058 shares of the specialty pharmaceutical company's stock worth $131,000 after purchasing an additional 91 shares during the last quarter. Bessemer Group Inc. lifted its holdings in Jazz Pharmaceuticals by 0.3% during the fourth quarter. Bessemer Group Inc. now owns 26,932 shares of the specialty pharmaceutical company's stock valued at $3,317,000 after purchasing an additional 92 shares in the last quarter. CIBC Asset Management Inc lifted its position in shares of Jazz Pharmaceuticals by 5.2% in the fourth quarter. CIBC Asset Management Inc now owns 1,972 shares of the specialty pharmaceutical company's stock valued at $243,000 after acquiring an additional 97 shares in the last quarter. Synovus Financial Corp raised its position in shares of Jazz Pharmaceuticals by 0.5% during the fourth quarter. Synovus Financial Corp now owns 19,206 shares of the specialty pharmaceutical company's stock valued at $2,365,000 after buying an additional 100 shares during the last quarter. Finally, Quarry LP grew its stake in Jazz Pharmaceuticals by 6.3% during the fourth quarter. Quarry LP now owns 1,700 shares of the specialty pharmaceutical company's stock valued at $209,000 after acquiring an additional 100 shares in the last quarter. 89.14% of the stock is owned by hedge funds and other institutional investors.

Insider Transactions at Jazz Pharmaceuticals

In other news, CEO Bruce C. Cozadd sold 1,500 shares of the company's stock in a transaction dated Tuesday, April 1st. The stock was sold at an average price of $123.75, for a total value of $185,625.00. Following the sale, the chief executive officer now owns 440,307 shares in the company, valued at $54,487,991.25. This represents a 0.34% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Seamus Mulligan purchased 100,000 shares of the stock in a transaction on Friday, May 9th. The shares were acquired at an average price of $98.26 per share, for a total transaction of $9,826,000.00. Following the transaction, the director now directly owns 100,000 shares of the company's stock, valued at $9,826,000. This represents a ∞ increase in their position. The disclosure for this purchase can be found here. Over the last ninety days, insiders sold 3,000 shares of company stock worth $355,925. Company insiders own 4.30% of the company's stock.

Analysts Set New Price Targets

A number of research analysts recently weighed in on JAZZ shares. Royal Bank Of Canada cut their target price on shares of Jazz Pharmaceuticals from $182.00 to $172.00 and set an "outperform" rating for the company in a report on Wednesday, May 7th. Cantor Fitzgerald downgraded shares of Jazz Pharmaceuticals from an "overweight" rating to a "neutral" rating and raised their price objective for the stock from $140.00 to $150.00 in a research note on Wednesday, February 26th. Needham & Company LLC reiterated a "buy" rating and issued a $202.00 target price on shares of Jazz Pharmaceuticals in a research note on Wednesday, June 11th. Truist Financial upped their target price on shares of Jazz Pharmaceuticals from $220.00 to $230.00 and gave the stock a "buy" rating in a research note on Thursday, March 6th. Finally, Barclays reiterated an "overweight" rating and issued a $200.00 target price (up from $190.00) on shares of Jazz Pharmaceuticals in a report on Thursday, February 27th. Two investment analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the company. According to MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and a consensus target price of $184.00.

Jazz Pharmaceuticals Stock Up 0.4%

Shares of JAZZ traded up $0.39 during midday trading on Thursday, hitting $107.51. 678,675 shares of the company's stock traded hands, compared to its average volume of 827,044. Jazz Pharmaceuticals PLC has a 1 year low of $95.49 and a 1 year high of $148.06. The firm's fifty day moving average is $108.55 and its 200-day moving average is $119.66. The company has a current ratio of 3.38, a quick ratio of 2.97 and a debt-to-equity ratio of 1.28. The stock has a market capitalization of $6.51 billion, a price-to-earnings ratio of 14.33, a price-to-earnings-growth ratio of 4.62 and a beta of 0.33.

Jazz Pharmaceuticals (NASDAQ:JAZZ - Get Free Report) last issued its quarterly earnings results on Tuesday, May 6th. The specialty pharmaceutical company reported $1.68 earnings per share for the quarter, missing the consensus estimate of $4.65 by ($2.97). Jazz Pharmaceuticals had a return on equity of 26.62% and a net margin of 11.86%. The business had revenue of $897.84 million during the quarter, compared to analyst estimates of $984.16 million. During the same period in the prior year, the business posted $2.68 EPS. Jazz Pharmaceuticals's revenue was down .5% compared to the same quarter last year. As a group, sell-side analysts anticipate that Jazz Pharmaceuticals PLC will post 16.96 earnings per share for the current year.

Jazz Pharmaceuticals Profile

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.